{"id":8059,"date":"2023-04-24T15:18:21","date_gmt":"2023-04-24T13:18:21","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf"},"modified":"2023-04-24T15:19:15","modified_gmt":"2023-04-24T13:19:15","slug":"230424_fr_maatpharma-reponse-fda_final-2","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-u-s-fda-lifts-clinical-hold-on-phase-3-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/230424_fr_maatpharma-reponse-fda_final-2\/","title":{"rendered":"230424_FR_MaaTPharma Re\u0301ponse FDA_FINAL"},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-8059","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>230424_FR_MaaTPharma Re\u0301ponse FDA_FINAL | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf\",\"url\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf\",\"name\":\"230424_FR_MaaTPharma Re\u0301ponse FDA_FINAL | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2023-04-24T13:18:21+00:00\",\"dateModified\":\"2023-04-24T13:19:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease\",\"item\":\"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-u-s-fda-lifts-clinical-hold-on-phase-3-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"230424_FR_MaaTPharma Re\u0301ponse FDA_FINAL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"230424_FR_MaaTPharma Re\u0301ponse FDA_FINAL | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf","url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf","name":"230424_FR_MaaTPharma Re\u0301ponse FDA_FINAL | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2023-04-24T13:18:21+00:00","dateModified":"2023-04-24T13:19:15+00:00","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease","item":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-u-s-fda-lifts-clinical-hold-on-phase-3-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/"},{"@type":"ListItem","position":3,"name":"230424_FR_MaaTPharma Re\u0301ponse FDA_FINAL"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf'>230424_FR_MaaTPharma Re\u0301ponse FDA_FINAL<\/a><\/p>\n"},"caption":{"rendered":"<p>230424_FR_MaaTPharma Re\u0301ponse FDA_FINAL<\/p>\n"},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{"filesize":121075,"sizes":{}},"post":8061,"source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf","_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media\/8059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=8059"}]}}